Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), brain disorder, central nervous system cancer, central nervous system disorder, ependymoma, epithelial neoplasm, glioma, meningioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, oligodendroglioma, primitive neuroectodermal tumor, tumor of meninges, vascular cancer	Active, not recruiting	Phase 2	2026-07-10		NCT03220646

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Eli Lilly and Company	370
Memorial Sloan Kettering Cancer Center	753

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hartford Healthcare Cancer Institute @ Hartford Hospital (Data Collection Only)	Hartford	United States	3
Lehigh Valley Health Network	Allentown	United States	35
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge	United States	56
Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale	United States	82
Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	United States	230
Memorial Sloan Kettering Commack (All Protocol Activities)	Commack	United States	20
Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown	United States	92
Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison	United States	86